EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice

E Gómez, J L Montero, E Molina, L García-Buey, M Casado, J Fuentes, M A Simón, A Díaz-González, F Jorquera, R M Morillas, J Presa, M Berenguer und 24 weitere

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von E Gómez und 35 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario 12 De Octubre, Madrid, Spain. Hauptthemen laut MEDLINE: Chenodeoxycholic Acid, Ursodeoxycholic Acid, Liver Cirrhosis, Biliary, Drug Therapy, Combination. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Suboptimal response to ursodeoxycholic acid occurs in 40% of primary biliary cholangitis (PBC) patients, affecting survival. Achieving a deep response (normalisation of alkaline phosphatase [ALP] and bilirubin ≤0.6 upper limit of normal) improves survival. Yet, the long‐term effectiveness of second‐line treatments remains uncertain.

Aims

To evaluate the long‐term effectiveness of obeticholic acid (OCA) ± fibrates. Focusing on biochemical response (ALP ≤1.67 times the upper limit of normal, with a decrease of at least 15% from baseline and normal bilirubin levels), normalisation of ALP, deep response and biochemical remission (deep response plus aminotransferase normalisation).

Methods

We conducted a longitudinal, observational, multicentre study involving ursodeoxyccholic acid non‐responsive PBC patients (Paris‐II criteria) from Spain and Portugal who received OCA ± fibrates.

Results

Of 255 patients, median follow‐up was 35.1 months (IQR: 20.2–53). The biochemical response in the whole cohort was 47.2%, 61.4% and 68.6% at 12, 24 and 36 months. GLOBE‐PBC and 5‐year UK‐PBC scores improved ( p < 0.001). Triple therapy (ursodeoxycholic acid plus OCA plus fibrates) had significantly higher response rates than dual therapy ( p = 0.001), including ALP normalisation, deep response and biochemical remission ( p < 0.001). In multivariate analysis, triple therapy remained independently associated with biochemical response ( p = 0.024), alkaline phosphatase normalisation, deep response and biochemical remission ( p < 0.001). Adverse effects occurred in 41.2% of cases, leading to 18.8% discontinuing OCA. Out of 55 patients with cirrhosis, 12 developed decompensation. All with baseline portal hypertension.

Conclusion

Triple therapy was superior in achieving therapeutic goals in UDCA‐nonresponsive PBC. Decompensation was linked to pre‐existing portal hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chenodeoxycholic AcidUrsodeoxycholic AcidLiver Cirrhosis, BiliaryDrug Therapy, CombinationAlkaline PhosphataseCholagogues and CholereticsHumansMaleFemaleMiddle AgedLongitudinal StudiesAgedTreatment OutcomeFibric AcidsSpainBilirubinAdult

Substanzen

Chenodeoxycholic AcidUrsodeoxycholic AcidAlkaline PhosphataseCholagogues and CholereticsFibric AcidsBilirubinobeticholic acid

Autor:innen und Institutionen

  • Hospital Universitario 12 De Octubre, Madrid, Spain.
  • Hospital Universitario Reina Sofia, Córdoba, Spain.
  • Complexo Hospitalario Universitario De Santiago, Coruña, Spain.
  • Hospital Universitario De La Princesa, Madrid, Spain.
  • Hospital Universitario de Torrecárdenas, Almería, Spain.
  • Hospital Universitario Miguel Servet, Zaragoza, Spain.

ORCID-Profile: A Olveira, I Garrido, S Rodríguez-Tajes, C M Fernández-Rodríguez

Zitieren

APA

Gómez, E., Montero, J. L., Molina, E., García-Buey, L., Casado, M., Fuentes, J., Simón, M. A., Díaz-González, A., Jorquera, F., Morillas, R. M., Presa, J., Berenguer, M., Conde, M. I., Olveira, A., Macedo, G., Garrido, I., Hernández-Guerra, M., Olivas, I., Rodríguez-Tajes, S., …, & Fernández-Rodríguez, C. M. (2024). Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18004

Vancouver

Gómez E, Montero JL, Molina E, García-Buey L, Casado M, Fuentes J, et al. Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18004

BibTeX
@article{Gmez2024,
  author = {Gómez, E and Montero, J L and Molina, E and García-Buey, L and Casado, M and Fuentes, J and Simón, M A and Díaz-González, A and Jorquera, F and Morillas, R M and Presa, J and Berenguer, M and Conde, M I and Olveira, A and Macedo, G and Garrido, I and Hernández-Guerra, M and Olivas, Ignasi and Rodríguez-Tajes, S and Londoño, M and Sousa, J M and Ampuero, J and Romero-González, E and González-Padilla, Sh and Escudero-García, D and Carvalho, A and Santos, A and Gutiérrez, M L and Pérez-Fernández, E and Aburruza, L and Uriz, J and Gomes, D and Santos, L and Martínez-González, J and Albillos, A and Fernández-Rodríguez, C M},
  title = {Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18004}
}
Kostenlos starten →